ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar996

Unlocking the Power of Stem Cells for Healing and Regrowth in Parkinson's Disease

Kella Devika; Dr. N. Phani Satyavathi; Ch. Bhargavi; E. Varshitha

Sri Venkateswara College of Pharmacy

Publication Date: 2025/03/28

Abstract: Parkinson's disease (PD) may be a dynamic neurological disorder brought on by dopaminergic neuron loss in the substantia nigra, a fundamental location of the brain effective for guiding development. The unfortunate fate of these neurons results in a deficiency in dopamine, a neurotransmitter vital for engine control, which produces symptoms including tremor, solidity, bradykinesia (graduality of development), and postural flimsiness, adjacent non-motor complications including cognitive decay and disposition clusters follow. Stem cell treatment addresses the basic causes of PD, thereby reflecting a transforming wilderness in care. This method suggests to replace the lost or damaged neurons, reestablish dopamine creation, and maybe stop or switch malady movement by using the one-of-a-kind regenerative capacity of stem cells. Actuated pluripotent stem cells (iPSCs), rebuilt from grown-up cells and advertising a patient-specific, moral elective; key stem cells investigated incorporate embryonic stem cells, which have tall pluripotency and can separate into dopaminergic neurons; mesenchymal stem cells, known for their neuroprotective and anti-inflammatory properties. This article examines the intricate factors via which stem cells interact with the damaged neuronal environment, facilitating healing and regeneration. It also covers important issues including moral questions, tumorigenicity, safe dismissal, and therapeutic adaptability. Moreover, it emphasizes developments in clinical trials, counting efforts to make strides cell conveyance techniques, increase cell survival, and guarantee useful integration into the brain's circuitry. By not as it was supervising signs but rather by addressing the root cause of neuronal misfortune, stem cell treatment eventually has the potential to transform Parkinson's disease treatment advertising trust for forward persistent outcomes and quality of life.

Keywords: *Parkinson's Disease, Dopamine, Stem Cells , Pathological Mechanism , Midbrain Dopaminergic Neurons, Future Perspectives In Parkinson's Disease.*

How to Cite: Kella Devika; Dr. N. Phani Satyavathi; Ch. Bhargavi; E. Varshitha (2025) Unlocking The Power of Stem Cells for Healing and Regrowth in Parkinson's Disease. *International Journal of Innovative Science and Research Technology*, 10(3), 1249-1254. https://doi.org/10.38124/ijisrt/25mar996

I. INTRODUCTION

A brain condition somewhat frequent in neurodegenerative diseases is Parkinson's disease, PD. Above 65 years of age, more than 2% of the population suffers with Parkinson's disease, PD. {1} Promising new field of research for treating Parkinson's disease that generates dopamine-a chemical helping to slow down death off is stem cell treatment. Symptoms including stiffness, problems with balance and movement follow from this loss. Although current Parkinson's disease, PD, medication can help improve symptoms, it cannot stop or undo the brain damage done. [3] But the damage to nerve cells and the course of Parkinson's disease varies significantly and influence many distinct parts of the brain. Furthermore, increasingly acknowledged are the pathophysiology of Parkinson's disease's crucial involvement of non-neuronal cells like astrocytes, oligodendrocytes, and microorganisms. For decades, cellular transplantation has been investigated as a Parkinson's disease therapeutic modality; stem cells are now the main source of regenerative treatment techniques.[4] Furthermore, Parkinson's disease is a complicated, multisystem condition involving areas outside the substantia nigra, therefore it displays symptoms that do not react to levodopa in addition to main motor symptoms. Furthermore, data from genetic, pharmacological, immunological, neuroimaging, and epidemiological investigations point to neuroinflammation as being very important for Parkinson's disease's course.[5] The most recent developments in stem cells research for Parkinson's disease, the challenges encountered, and the hope stem cell treatment holds to reorganize treatment and improve the quality of life for people affected by these crippling diseases are investigated in this paper.

II. ELUCIDATING THE MULTI-FACTORIAL PATHOPHYSIOLOGY OF PARKINSON'S DISEASE

A complex neurodegenerative disease, Parkinson's disease, PD, is typified by the steady degradation of the mind-producing neurons in the substantia nigra causing

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar996

incapacitating motor symptoms like slow movement[bradykinesia] stiffness, and involuntary tremor. [6] Extensive studies have mostly confirmed that the major cause of the disease is the aggregation of a protein called Alpha-synuclein, which creates harmful clusters known as Lewy bodies in brain cells. [7] In both sporadic and familial Parkinson's disease, alpha-synuclein protein accumulation helps to explain brain cells death. [8] Parkinson's disease also results in great part from inflammation. High quantities of damaging substances [cytokines] that induce inflammation and activated immune cells[microglia] in afflicted brain areas reflect this. Furthermore, contributing to the degeneration of dopaminergic neurons in the brain is the inflammatory reaction there. [9] Due to damage to energy producing mitochondrial complex I and mitochondrial function problems which cause cell damage [oxidative stress], energy loss, and cellular imbalance, mitochondrial problems are another important factor in the development of Parkinson's disease mostly affecting the brain cells that produce dopamine in the substantia nigra. causing death in dopamine neurons. [10] These genes relate to inherited Parkinson's disease. [11] Furthermore in charge of breaking down and eliminating are the proteasome and autophagy processes. Parkinson's disease compromises the ability to remove damaged proteins and organelles. Damage to proteins like alpha-nuclein therefore accumulates inside neurons, causing toxicity and more neurological malfunction. These revelations regarding the fundamental causes of Parkinson's disease offer a foundation for developing medicines meant to protect dopamine-producing brain cells and slow down the course of the illness.

III. INVESTIGATING DIVERSE STEM CELLS TYPES IN PROGRESSIVE PARKINSON'S DISEASE

- *Embryonic Stem Cells[ecss]-*

Negral Dopaminergic Neurons are among the pluripotent cells derived from the inner cell mass of a blastocyst that could develop into any kind of cell type within the body [13]. Human ECSCs, meantime, provide dopamine and generate neurons for PD transplantation. [14] Translocated into a striatum of animal models with Parkinson's disease, dopaminergic neurons generated from embryonic pluripotent stem cells have shown ability to restore function. Still, major questions surround these cells' use in treating Parkinson's and other neurodegenerative illnesses. Tumor growth is a main concern; hence, inhibiting cell division before transplantation, cell selection, and long maturation in the lab help to reduce this risk. Following the implantation of ECSCs or neural stem cells produced from embryonic pluripotent cells, many animal trials have shown modest to moderate improvement in PD symptoms. [15, 17]

- *Mesenchymal Stem Cells [MSCs]-*

Found in different tissues including bone marrow and adipose tissue, these are multipotent stem cells. Bone marrow-derived meson mineral stem cells, BMSCs, are the most often researched MSC kind. Among other sites of MCSCs are the umbilical cord, peripheral blood, skin, etc. 18 [18] MSCs topologically resemble fibroblasts with elongated, thin cell bodies and a conspicuous nucleus. Stem cells, MSCs have great capacity to self-renew while maintaining their multipotent character, just like other tissues. [19] MSCs also protect dopaminergic neurons from degeneration in human and animal studies. {20} MSCs have shown promise as rectors for treating a variety of central nervous system diseases according certain experimental research. [20,21] A crucial consideration in treating neurodegenerative disease is the ability of MSCS to develop specific neurons, which these results also revealed. [22] MSCS was used in some clinical trials treating PD. For one research, for instance, individuals needed their own BMSCS bone marrow cancer and were tracked for up to 36 months. These studies revealed some improvement without generating malignancies or other adverse consequences. MSCS seems bright for treating PD, however additional research is required to verify its safety and efficacy. [23]

- *Induced Pluripotent Stem Cells [IPSS]-*

Usually derived from mature cells such as fibroblasts, induced pluripotent stem cells [iPSCs] are produced by adding particular factors that encourage cell renewal and pluripotency, especially POU5F1, SOX2, KIF4, and MYC. [24, 25] Apart from its capacity to cell renew and differentiate into distinct cell types, iPSCs also have benefits for cell replacement treatments. Direct generation of them from a patient's own cells could help reduce the danger of transmissible diseases and immunological rejection following cell treatment. [26] [Induced pluripotent stem cells, iPSCs, show great promise according several basic and clinical studies. One important strategy in Parkinson's disease is PD treatment in regeneration of dopaminergic neurons. These cells implanted into the stratum has proved to reduce Parkinson's disease symptoms. [23,27,28,29] Although IPSCS provides numerous benefits, clinical transplants find them difficult because of the possibility of tumour development, which causes great worry. IPSCS should be used for PD treatment under safety. Before taking IPSCS research from the lab to actual clinical uses, it is imperative to identify strategies to diminish this tumour risk and minimize chances of genetic alterations. [30, 31]

IV. ADVANCEMENTS IN PRE-CLINICAL STUDIES FOR PARKINSON'S DISEASE

With stem cell therapies, especially embryonic stem cells [ESC], and induced pluripotent stem cells[IPSCS], animal models of Parkinson's disease have demonstrated hopeful outcomes in preclinical research. These stem cells can develop dopamine-producing neurons, the kind lacking in Parkinson's disease when human ESC-derived dopaminergic neurons are implanted into the brain particularly in the striatum. Of these models, they not only survive and interact with current brain circuits but also show promise for future therapies in helping recover motor ability. [31,32,33] By effectively grafting into the brain, creating connections within the host striatum and hence helping to lower motor symptoms, IPSC-derived documented neurons have showed encouraging effects in Parkinson's disease animals. In preclinical investigations, this shows their capacity to restore dopamine activity and enhance

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar996

movement capacity. [34, 35] Still unresolved, nevertheless, are issues like limited survival of transplanted cells, uneven differentiation, and risk of tumor development. For their capacity to protect neurons and control immune response, PDS models have also investigated mesenchymal stem cells, MSCS. [36] PD models have looked at MSCS for neuron protection. Leveraging their neuroprotective and immune-regulating qualities, PD models have investigated MSCS for their capacity to protect neurons and lower inflammation in the brain. [37,38]

V. CLINICAL TRIALS

Safety and efficacy of stem cell treatments for multiple sclerosis [MS] sufferers have been investigated in several clinical studies. Aiming to reset the immune system and limit disease progress, autologous hematopoietic stem cell transplantation [AHSCT] has showed potential as a therapy for aggressive MS. [39] Modifying treatments [AHSCT] proved to be more successful in stopping progression and affecting neurological function than in typical disease. Many individuals, according to long-term research, continue free from MS symptoms five years or more following AHSCT treatment. [39,41] For some patients, some studies reveal encouraging findings with long-term stabilization or disability improvement. The operation is only utilized for individuals with very active MS at now, though, and has major hazards. [41, 43] Mostly, clinical studies involving MSCs in MS patients have been concerned in assessing its safety and practically. 43 Usually well-tolerated, infusing autologous MSCs through an IV has shown promise in lowering inflammation and promoting nerve protection. [44) Confirming the long-term safety and efficacy of MS-C based treatments for MS requires more sizable randomized studies. [45]

VI. CHALLENGES AND FUTURE DIRECTIONS

Although stem cell treatments for multiple sclerosis MS show great promise, they provide major difficulties guaranteeing that transplanted cells survive, develop into the proper cell types such as neurons or oligodendrocytes, and functionally integrate into the central nervous system in complicated. Inflammation, immunological responses, and current tissue injury can all make the host CNS environment unfriendly and constrain the cell's capacity for survival and effective repair of damaged neuronal networks. [46] Research on techniques to increase graft survival and promote directed migration of transplanted cells to sites of demyelination is in active progress. These techniques seek to improve the effectiveness of stem cell treatments by guaranteeing that the transplanted cells not only survive but also negotiate effectively to the areas requiring repair. This can entail changing the microenvironment or applying bioengineering methods to guide stem cells to the injured sites, therefore assuring their efficient integration and support of tissue regeneration. [46] The possibility of graft rejection or secondary autoimmunity—where the immune system attacks the transplanted cells or the body's own tissues—adds still another difficulty. This can happen when the immune system targets healthy cells following the operation or detects the transplanted cells as alien. Along with the improvement in increased immunosuppressive treatments, the use of autologous (patient-derived) or genetically modified stem cells may help lower the risks of graft rejection and subsequent autoimmune. These techniques seek to reduce immunological reactions that might compromise the efficacy of the treatment and increase the fit of the transplanted cells with the patient's immune system. [49] Future developments in stem cell therapy for MS could involve the use of gene editing technology to create off-the-shelly cell products with improved capability for remyelination or immune regulation. This method could enable the development of standardized, easily available stem cell treatments more successful in mending damaged myelin and controlling the immune system, so providing possibly more easily available and effective treatment choices for MS patients. Fifty [50] Future developments in stem cell therapy for MS could involve the use of gene editing technology to create off-the-shelly cell products with improved capability for remyelination or immune regulation. This method could enable the development of standardized, easily available stem cell treatments more successful in mending damaged myelin and controlling the immune system, so providing possibly more easily available and effective treatment choices for MS patients. [51} Early research on stem cell therapies for multiple sclerosis (MS) has showed encouraging outcomes, so providing hope for improved treatments going forward. Although there are still difficulties, developments in cell manufacture, genetic engineering, and biomaterials should make these treatments safer, more efficient, and more easily available. Finding the ideal therapeutic approaches and knowing the long-term advantages calls for more study and clinical trials. Now included into therapy recommendations, autologous hematopoietic stem cell transplantation (AHSCT) has proven efficacy in treating very active relapse MS unresponsive to other treatments. Younger patients with active disease would benefit most from it, though, and cautious patient selection is crucial given the hazards involved in the surgery. Studies examining its use for progressive MS also help to improve AHSCT techniques and lower dangers by means of ongoing research. Furthermore, under investigation are mesenchymal stem cell treatments' capacity to shield nerves and encourage recovery in MS.

VII. DISCUSSION

Stem cells offer various challenges even if their application for Parkinson's disease has significant possibilities. Particularly dopamine-producing cells lost in Parkinson's disease, stem cell treatments aim to heal brain's damaged neurons. Studies show that stem cells can grow into dopaminergic neurons, therefore maybe improving motor performance and lowering symptoms. Still, there are several big challenges to go including ensuring the life and suitable integration of given cells, preventing immunological rejection, and managing the risk of tumour formation. Furthermore, covered are moral questions about the usage of embryonic stem cells and the complexity of long-term effects.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar996

VIII. CONCLUSION

Although their application for Parkinson's illness has great potential, stem cells present several difficulties as well. Particularly dopamine-producing cells, lost in Parkinson's disease, stem cell treatments seek to repair damaged neurons in the brain. Studies have indicated that stem cells can develop into dopaminergic neurons, therefore perhaps enhancing motor ability and reducing symptoms. Still, there are major obstacles to overcome include guaranteeing the life and appropriate integration of donated cells, avoiding immunological rejection, and controlling the danger of tumour development. Additionally addressed are ethical issues about the use of embryonic stem cells and the intricacy of long-term results. Furthermore, unrealized are the cost-effectiveness and scalability of stem cell therapies. In summary, even although stem cell therapy for Parkinson's disease shows great promise for research, more studies and clinical trials are required to prove its safety, effectiveness, and pragmatic relevance in treating the illness.

REFERENCES

[1]. D.J Anderson Stem cells and pattern formation in the nervous system The possible versus the actual Neuron (2001)

[2]. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006;

[3]. Ola now CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999

[4]. Parmar, M, Grealish, S, and Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. (2020) 21:103–15. Doi: 10.1038/s41583-019-0257-7

[5]. Tansey, MG, Walling's, RL, Houser, MC, Herrick, MK, Keating, CE, and Joers, V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. (2022) 22:657–73. Doi: 10.1038/s41577-022-00684-6

[6]. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39:889-909

[7]. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006; 52:33-38

[8]. Henderson MX, Trojanowski JQ, Lee VM. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies. Neurosci Lett 2019;709:134316

[9]. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. TransNeu-rodegener 2015; 4:19

[10]. Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci Ther 2017; 23:5-22

[11]. Chu YT, Tai CH, Lin CH, Wu RM. Updates on the genetics of Parkinson's disease: clinical implications and future treatment. Acta Neurol Taiwan 2021; 30:83-93

[12]. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci 2011; 31:14508-14520

[13]. Salehi M, Pasbakhsh P, Soleimani M, Abbasi M, Hasanzadeh G, Modaresi MH. et al. Repair of spinal cord injury by co-transplantation of embryonic stem cell-derived motor neuron and olfactory ensheathing cell. Iranian Biomedical Journal. 2009;13(3):125–35. [PubMed] [Google Scholar]

[14]. 36.Kim J-H, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N. et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418(6893):50–6. Doi: 10.1038/nature00900. [DOI] [PubMed] [Google Scholar]

[15]. Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L. et al. Transplantation of Human Embryonic Stem Cell-Derived Cells to a Rat Model of Parkinson's Disease: Effect of In Vitro Differentiation on Graft Survival and Teratoma Formation. Stem Cells. 2006;24(6):1433–40. doi: 10.1634/stemcells.2005-0393. [DOI] [PubMed] [Google Scholar]

[16]. Erdo F, Bührle C, Blank J, Hoehn M, Xia Y, Fleischmann B. et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. Journal of Cerebral Blood Flow & Metabolism. 2003;23(7):780–5. Doi: 10.1097/01.WCB.0000071886. 63724.FB. [DOI] [PubMed] [Google Scholar]

[17]. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y. et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. Journal of Clinical Investigation. 2005;115(1):102–9. Doi: 10.1172/JCI21137. [DOI] [PMC free article] [PubMed] [Google Scholar]

[18]. Nadri S, Soleimani M, Mobarra Z, Amini S. Expression of dopamine-associated genes on conjunctiva stromal-derived human mesenchymal stem cells. Biochemical and biophysical research communications. 2008;377(2):423–8. Doi: 10.1016/j.bbrc.2008.09.148. [DOI] [PubMed] [Google Scholar]

[19]. 1 Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., Moorman M. A., Simonetti D. W., Craig S., and Marshak D. R., Multilineage potential of adult human mesenchymal stem cells, Science. (1999) 284, no. 5411, 143–147, 2-s2.0-0033515827, https://doi.org/10.1126/science.284.5411.143.

[20]. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I. et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of neurology. 2010;67(10):1187. Doi: 10.1001/archneurol.2010.248. [DOI] [PMC free article] [PubMed] [Google Scholar]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar996

[21]. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proceedings of the National Academy of Sciences. 1999;96(19):10711–6. Doi: 10.1073/pnas.96.19.10711. [DOI] [PMC free article] [PubMed] [Google Scholar]
[22]. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinson's disease. 2012;2012 Doi: 10.1155/2012/873706. [DOI] [PMC free article] [PubMed] [Google Scholar]
[23]. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell stem cell. 2011;8(1):106–18. Doi: 10.1016/j.stem.2010.12.003. [DOI] [PMC free
[24]. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. cell. 2007;131(5):861–72. Doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]
[25]. 68.Su P, Loane C, Politis M. The Use of Stem Cells in the Treatment of Parkinsons Disease. In sciences J. 2011;1(3):136–56. [Google Scholar]
[26]. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinson's disease. 2012;2012 Doi: 10.1155/2012/873706. [DOI] [PMC free article] [PubMed] [Google Scholar]
[27]. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, Soldner F. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proceedings of the National Academy of Sciences. 2008;105(15):5856–61. Doi: 10.1073/pnas.0801677105. [DOI] [PMC free article] [PubMed] [Google Scholar]
[28]. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, Soldner F. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proceedings of the National Academy of Sciences. 2008;105(15):5856–61. Doi: 10.1073/pnas.0801677105. [DOI] [PMC free article] [PubMed] [Google Scholar]
[29]. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nature Reviews Cancer. 2011;11(4):268–77. Doi: 10.1038/nrc3034. [DOI] [PubMed] [Google Scholar]
[30]. Moriguchi H, Chung RT, Sato C. Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. Hepatology. 2010;51(3):1088–9. Doi: 10.1002/hep.23396. [DOI] [PubMed] [Google Scholar]
[31]. Francis NL, Zhao N, Calvelli HR, Saini A, Giford JJ, Wagner GC, Cohen RI, Pang ZP, Moghe PV. Peptide-based scafolds for the culture and transplantation of human dopaminergic neurons. Tissue Eng Part A. 2020;26(3–4):193–205.
[32]. Cardoso T, Adler AF, Mattsson B, Hoban DB, Nolbrant S, Wahlestedt JN, A, Grealish S, Björklund A, Parmar M. Target-specific forebrain projections and appropriate synaptic inputs of he SC-derived dopamine neurons grafted to the midbrain of Parkinsonian rats. J Comp Neurol. 2018;526(13):2133–46
[33]. Wakeman DR, Hiller BM, Marmion DJ, McMahon CW, Corbett GT, Mangan KP, Ma J, Little LE, Xie Z, Perez-Rosello T, Guzman JN. Cryopreservation maintains functionality of human iPSC dopamine neurons and rescues Parkinsonian phenotypes in vivo. Stem Cell Rep. 2017;9(1):149–61.
[34]. Petrus-Reurer S, Kumar P, Padrell Sánchez S, Aronsson M, André H, Bartuma H, Plaza Reyes A, Nandrot EF, Kvanta A, Lanner F. Preclinical safety studies of human embryonic stem cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration. Stem Cells Trans Med. 2020;9(8):936–5
[35]. Shokravi S, Borisov V, Zaman BA, Niazvand F, Hazrati R, Khah MM, Thangavelu L, Marzban S, Sohrabi A, Zamani A. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review. Stem Cell Res Ther. 2022;13(1):192.
[36]. Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE Jr. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017;525(3):498–512.
[37]. Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE Jr. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017;525(3):498–512.
[38]. Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies. Int J Mol Sci. 2020;21(22):8662
[39]. Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies. Int J Mol Sci. 2020;21(22):8662.
[40]. Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Sclera J. 2018;24(4):501–11.
[41]. Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Sclera J. 2018;24(4):501–11.
[42]. Horak J, Nalos L, Martinkova V, Tegl V, Vistejnova L, Kuncova J, Kohoutova M, Jarkovska D, Dolejsova M, Benes J, Stengl M. Evaluation of mesenchymal stem cell therapy for sepsis: a randomized controlled porcine study. Front Immunol. 2020;7(11):126.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25mar996

[43]. Yang G, Van Kaer L. Therapeutic targeting of immune cell autophagy in multiple sclerosis: Russian roulette or silver bullet? Front Immunol. 2021;31(12): 724108.
[44]. Yuan TF, Dong Y, Zhang L, Qi J, Yao C, Wang Y, Chai R, Liu Y, So KF. Neuromodulation-based stem cell therapy in brain repair: recent advances and future perspectives. Neurosci Bull. 2021; 37:735
[45]. Bose G, Thebault S, Rush CA, Atkins HL, Freedman MS. Autologous hematopoietic stem cell transplantation for multiple sclerosis: a current perspective. Mult Sclera J. 2021;27(2):167–73.
[46]. Barati S, Tahmasebi F, Faghihi F. Effects of mesenchymal stem cells transplantation on multiple sclerosis patients. Neuropeptides. 2020;1(84): 102095.
[47]. Barati S, Tahmasebi F, Faghihi F. Effects of mesenchymal stem cells transplantation on multiple sclerosis patients. Neuropeptides. 2020;[84]:102095
[48]. Tupone MG, D'Angelo M, Castelli V, Catanesi M, Benedetti E, Cimini. A state-of-the-art of functional scafolds for 3D nervous tissue regeneration. Front Bioeng Biotechnol. 2021;18(9): 639765.
[49]. Konovalova J, Gerasymchuk D, Parkkinen I, Chmielarz P, Domanskyi A. Interplay between MicroRNAs and oxidative stress in neurodegenerative diseases. Int J Mol Sci. 2019;20(23):6055.
[50]. Farina M, Vieira LE, Buttari B, Profumo E, Saso L. The Nrf2 pathway in ischemic stroke: a review. Molecules. 2021;26(16):5001.
[51]. Wu L, Lu J, Lan T, Zhang D, Xu H, Kang Z, Peng F, Wang J. Stem cell therapies: a new era in the treatment of multiple sclerosis. Front Neurol. 2024;9(15):1389697. 53